<DOC>
	<DOCNO>NCT02107079</DOCNO>
	<brief_summary>The circadian rhythm , sleep-wake cycle , mainly regulate melatonin . The synthesis melatonin stimulate absence light , lead peak serum level bedtime . In human , endogenous `` signal '' neurohormone induce sleep . Exogenous melatonin beneficial different sleep disturbance include delayed sleep phase insomnia , melatonin- deficiency-related insomnia ( especially elderly ) shift work sleep disorder . Melatonin know low variable bioavailability human due high first pas effect variable pharmacokinetics short half-life . In order prevent exposure patient unnecessary high dosage melatonin order achieve short Tmax high bio-availability melatonin , proper formulation need define . This study , three-phased cross-over study , aim define proper formulation oral oromucosal melatonin treatment insomnia investigate Tmax relative bioavailability derive melatonin level salivary sample healthy volunteer administration melatonin different formulation : 2,5mg melatonin immediate release capsule ( produce Apotheek UMCU ) , 1mg melatonin immediate release tablet ( produce Tiofarma ) , low-dose 0.1mg melatonin original Sleepzz tablet ( produce Vemedia Manufacturing BV ) .</brief_summary>
	<brief_title>The Relative Bio-availability Oral Oromucosal Melatonin Different Formulations Healthy Human Volunteers .</brief_title>
	<detailed_description>The circadian rhythm , sleep-wake cycle , mainly regulate melatonin . The synthesis melatonin stimulate absence light , lead peak serum level bedtime . In human , endogenous `` signal '' neurohormone induce sleep . Exogenous melatonin beneficial different sleep disturbance include delayed sleep phase insomnia ( Dahlitz et al . 1991 , Regestein et al . 1995 ) , melatonin- deficiency-related insomnia ( especially elderly ) ( Garfinkel 1995 , Etzioni et al . 1995 ) shift work sleep disorder ( Folkard et al . 1993 , Skene et al . 1996 ) . A randomized controlled trial van Geijlswijk et al . ( van Geijlswijk 2010 ) show relationship could demonstrate melatonin dose ( 0.05-0.15 mg/kg ) shift sleep onset time ( SOT ) , shorten sleep onset latency ( SOL ) shift dim light melatonin ( DLMO ) . On hand , time melatonin administration clinically statistically significant effect three parameter . Timing melatonin administration relation baseline DLMO determine phase advance , measure shift DLMO SOT early time evening , result also short SOL . Melatonin must administer closely defined time-slot endogenous DLMO bedtime . The phase advance occur melatonin administer 1-2 hour DLMO bedtime ( van Geijlswijk et al . 2010 ) . This trial demonstrate low dosage melatonin ( 0.05mg/kg ) effective child give least 1-2 hour individual DLMO desire bedtime . This mean release melatonin pharmaceutical formulation occur fast enough order achieve predictive high level within desire time-slot occurrence ( baseline ) DLMO induce phase advance . These high maximum serum level shortly administration ( Tmax ) mean release rate melatonin formulation need fast possible bioavailability need high possible . Melatonin know low variable bioavailability human due high first pas effect variable pharmacokinetics short half-life . In order prevent exposure patient unnecessary high dosage melatonin order achieve short Tmax high bio-availability melatonin , proper formulation need define . Thereby , bioavailability must make less variable order understand biologic effect melatonin ( Di 1997 ) . Aim/objective . This study , three-phased cross-over study , aim define proper formulation oral oromucosal melatonin treatment insomnia investigate Tmax relative bioavailability derive melatonin level salivary sample healthy volunteer administration melatonin different formulation : 2,5mg melatonin immediate release capsule ( produce Apotheek UMCU ) , 1mg melatonin immediate release tablet ( produce Tiofarma ) , low-dose 0.1mg melatonin original Sleepzz tablet ( produce Vemedia Manufacturing BV ) . Study-design . Three-phased cross-overstudy . Study-population . The study population consist 10 healthy volunteer ( male ) age 18 35 year old without insomnia . They recruit Netherlands . Intervention . The intervention start 10:00 11:00 participant flush mouth water , wait 15 minute start chew cotton plug 1 minute . Directly participant administer one IMP 's accord instruction . The tablet capsule swallow . The sublingual tablet administer sublingual . 10 minute administration subject drink one glass water subsequently try swallow much liquid ( include saliva ) , order prevent contamination saliva sample remain exogenous melatonin . At 15 minute , 30 min , 1 hour , 1.5 hour , 2 hour 3 hour oral administration participant chew new cotton plug 1 minute . After administration sublingual tablet saliva sample collect 25 minute , 40 minute , 60 minute , 1.5 hour , 2 hour 3 hour sublingual administration . 15 minute sample subject flush mouth water . The cotton plug salivary preserve test-tube freezer analyze Ziekenhuis Gelderse Vallei . Main study endpoint : Tmax relative bioavailability oral oromucosal melatonin derive melatonin level salivary sample healthy volunteer . Nature extent burden risk associate participation , benefit group relatedness : This study burden participant small extent . As mentioned , melatonin well tolerate report hangover effect . Its rarely occur side effect include fatigue , dizziness , nausea , mild drowsiness , hypothermia headache ( Wagner 1998 , Waldhauser 1990 , Dahlitz 1991 , Garfinkel 1995 , Dollins 1994 ) . Besides , participant ask perform simple action 3 intervention day 3 hour . The low dose 0.1mg melatonin original Sleepzz table available without prescription drugstore Netherlands . The tablet also contain low dosage melatonin , respectively 1mg capsule contain regular dose melatonin ( 2,5mg ) . These dosage safe adult child . A report publish consequence long-term treatment melatonin human . ( Severe ) adverse event describe report . ( Van Geijlswijk 2011 , Jan et al . 1996 , Jan et al . 1994 , Gilberg et al . 1997 , Smits et al . 2001 , Arendt 2000 ) .</detailed_description>
	<mesh_term>Melatonin</mesh_term>
	<criteria>Volunteers ( male ) age 18 35 year old without insomnia . Lactose intolerance . Hepatic disease Kidney disease Autoimmune disease Depression Neurological disorder Oromucosal disease .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>melatonin</keyword>
	<keyword>bioavailability</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>